By Professor Sallie Pearson

Conference Presentations

Schaffer A; Nassar N; Bruno C; Buckley N; Cairns R; Litchfield M; Paget S; Zoega H; Pearson S, 2021, 'Prescribed Medicine Use in a Nationwide Sample of Australian Children: Extent of Off-Label Use', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, 23 August 2021 - 25 August 2021

Schaffer A; Brett J; Buckley N; Pearson S, 2021, 'Trajectories of Pregabalin Use and Their Association with Longitudinal Changes in Opioid and Benzodiazepine Daily Dose', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management, Virtual, 23 August 2021 - 25 August 2021

Schaffer A; Cairns R; Brown J; Gisev N; Buckley N; Pearson S, 2020, 'Changes in sales of over‐the‐counter and prescription medicines after rescheduling of codeine to a prescription‐only medicine in Australia', presented at International Conference on Pharmacoepidemiology and Therapeutic Risk Management

Daniels B, 2019, 'Identifying incident cancer cases in medicine dispensing claims: A validation study using Australia’s Pharmaceutical Benefits Scheme (PBS) data', presented at Asian Conference on Pharmacoepidemiology & Therapeutic Risk Management, 11 October 2019 - 13 October 2019

Daniels B; Pearson S, 2019, 'Understanding Treatment Pathways for HER2-Positive Metastatic Breast Cancer (HER2+MBC) Patients: Analysis Using Group-Based Trajectory Models (GBTM)', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Prague, Czechia, 24 August 2019 - 26 August 2019

Schaffer A; Buckley N; Pearson S, 2019, 'Unintended Consequences of a National Policy Intervention to Curb Inappropriate Alprazolam Prescribing in Australia', presented at International Conference on Pharmacoepidemiology and Drug Safety, Philadelphia, USA, 24 August 2019 - 28 August 2019, http://dx.doi.org/10.1002/pds.4864

Daniels B; Pearson S, 2017, 'Real-world use and outcomes of trastuzumab for HER2+ metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2015', presented at San Antonio Breast Cancer Symposium, San Antonio, TX, USA, 06 December 2017 - 10 December 2017

Daniels B; Pearson S, 2017, 'Patterns of care and outcomes for long-term survivors with HER2-positive metastatic breast cancer (HER2+MBC) starting trastuzumab: An Australian whole-of-population cohort study', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, 13 November 2017 - 15 November 2017

Daniels B; Pearson S, 2017, 'Did a policy to ease the prescribing restrictions for lapatinib as second-line HER2-positive metastatic breast cancer increase initiation rates?', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, QC, Canada, 26 August 2017 - 28 August 2018

Schaffer AL; Buckley NA; Dobbins TA; Degenhardt L; Larance B; Pearson S-A, 2017, 'Opioid Switching After Introduction of a Tamper-Resistant Oxycodone Formulation in Australia: A Population-Based Study', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000437103900349&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Daniels B; Pearson S, 2016, 'Real-word use and outcomes of trastuzumab for metastatic breast cancer in Australia: Analysis of the Herceptin Program, 2001 – 2014', presented at Clinical Oncology Society of Australia Annual Scientific Meeting, Gold Coast, QLD, 15 November 2016 - 17 November 2016

Daniels B; Pearson S, 2016, 'Tracking trastuzumab (H) therapy in early- through late-stage HER2-positive breast cancer (HER2+BC) in Australia: A national, retrospective cohort study', presented at International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 26 August 2016 - 29 August 2016

Schaffer AL; pearson S; buckley N, 2016, 'Does Concordance with Fixed-Dose Combination (FDC) Treatment Guidelines Improve Persistence? An Australian Population Based Cohort Study.', presented at 32nd International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Dublin, Ireland, 25 August 2016 - 28 August 2016, http://dx.doi.org/10.1002/pds.4070

joshi V; adelstein BA; Schaffer AL; srasuebkul P; EoCC Investigators ; dobbins T; pearson S, 2016, 'A Proxy of Cancer Progression in Dispensing Claims: Validation and Performance', presented at 29th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Montreal, Canada, 25 August 2016 - 28 August 2016, http://dx.doi.org/10.1002/pds.3512

Daniels B; Pearson S, 2016, 'Opportunities for post-market surveillance of high cost medicines in Australia: Observing trastuzumab-treated women from early- through late-stage HER2-positive breast cancer (HER2+BC)', presented at International Population Data Linkage Conference, Swansea, Wales, UK, 23 August 2016 - 26 August 2016, http://dx.doi.org/10.23889/ijpds.v1i1.142

Schaffer AL; Buckley NA; Dobbins T; Banks E; Pearson S-A, 2015, 'Time Series Analysis of the Impact of Adverse Media on Statin Dispensing and Discontinuation in Australia'

Vajdic CM; Schaffer A; Dobbins TA; Ward RL; Barrett J; Er CC; Pearson S-A, 2014, 'Health service utilisation and investigations before diagnosis of cancer of unknown primary (CUP): A population-based nested case-control study', presented at 2014 World Cancer Congress, Melbourne, 03 December 2014 - 06 December 2014, http://dx.doi.org/10.1111/ajco.12332

Vajdic CM; Schaffer A; Dobbins TA; Barrett J; Ward RL; Er CC; Pearson S-A, 2014, 'HEALTH SERVICE UTILISATION AND INVESTIGATIONS BEFORE DIAGNOSIS OF CANCER OF UNKNOWN PRIMARY (CUP): A POPULATION-BASED NESTED CASE-CONTROL STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000344745100020&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Daniels B; Ward R; Pearson S-A, 2013, 'DO PHARMACEUTICAL CLAIMS ACCURATELY REFLECT ONCOLOGY PRESCRIBING PRACTICE: EVIDENCE FROM AN AUSTRALIAN HER2+EARLY BREAST CANCER COHORT (HER2EBC)', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800200&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Schaffer AL; Pearson S-A; Dobbins T; Er C; Meagher NS; Barrett J; Ward RL; Vajdic CM, 2013, 'HEALTH SERVICE USE, TREATMENT PATTERNS, AND SURVIVAL FOR CANCER OF UNKNOWN PRIMARY: A DATA LINKAGE STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800129&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Harris C; Pearson S-A; Daniels B; Srasuebkul P; Ward R, 2013, 'HER2 POSITIVE EARLY BREAST CANCER (HER2EBC): AN AUSTRALIAN PATTERN OF CARE STUDY', https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000325868800073&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Stavrou E; Buckley N; Olivier J; Pearson S-A, 2012, 'Futile Drug Use at the End of Life? Continuation of Statins after a Cancer Diagnosis', presented at 28th International Conference on Pharmacoepidemiology & Therapeutic Risk Management, Barcelona, Spain, 23 August 2012 - 26 August 2012, http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=000308131701017&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Lu CY; Srasuebkul P; Drew A; Chen K; Ward R; Pearson S-A, 2011, 'Cardiotoxic Cancer Therapies in Australia: Which Patients Are Assessed for Cardiac Function?', Vol. 20, pp. S248 - S248, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000294946600550&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Pearson S; Ringland CL; Ward RL, 2008, 'Off-label trastuzumab use in Australia: Evidence from the national Herceptin Program for HER-2 positive metastatic breast cancer', Vol. 17, pp. S29 - S29, https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000258420100067&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=891bb5ab6ba270e68a29b250adbe88d1

Back to profile page